Session » (2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

Date: Tuesday, October 28, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 2247

A Pilot Study to identify novel autoantibody biomarkers in Rheumatoid Arthritis (RA) patients using Immunome Protein Array

10:30AM-12:30PM: Abstract Number: 2245

Add-on of Coronary Artery Calcium Score Significantly Improves the Risk Prediction of Cardiovascular Diseases in Patients with Rheumatoid Arthritis: From a Real-world Cohort Study

10:30AM-12:30PM: Abstract Number: 2242

Analysis of Bronchoalveolar Fluid Cytokine Profile as a Way to Understand the Lung Disease Associated with Systemic Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 2262

Assessment of small airway disease in rheumatoid arthritis

10:30AM-12:30PM: Abstract Number: 2252

Association between frailty and survival among older adults with rheumatoid arthritis and lung cancer

10:30AM-12:30PM: Abstract Number: 2254

Association of disease activity with insomnia, depression, and fatigue in patients with rheumatoid arthritis: a multicenter prospective observational study

10:30AM-12:30PM: Abstract Number: 2244

Bone Mineral Density Trajectories and Fracture Risk in Rheumatoid Arthritis: A 7-Year Longitudinal Analysis Using Group-Based Trajectory Modeling

10:30AM-12:30PM: Abstract Number: 2250

Clinical and Serological Predictors of Interstitial Lung Disease in Rheumatoid Arthritis: Are Anti-Citrullinated Protein Antibodies Truly Relevant?

10:30AM-12:30PM: Abstract Number: 2258

Clinical Associations of Pulmonary Hypertension in RA Patients with and without Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 2263

Comparison of a Patient-Reported Disease Activity Measure with Physician-Based Indices in Rheumatoid Arthritis Patients in Nigeria

10:30AM-12:30PM: Abstract Number: 2228

COVID-19 Outcomes in Rheumatoid Arthritis Patients Prescribed Biologic vs. Conventional DMARDs: A Propensity-Matched Analysis

10:30AM-12:30PM: Abstract Number: 2240

Diabetes Significantly Amplifies Risk of Cardiac Arrhythmias in Rheumatoid Arthritis Patients: Results from a Multi-Center Electronic Health Record Study

10:30AM-12:30PM: Abstract Number: 2255

Diagnostic Accuracy of Anti-Carbamylated Protein Antibodies in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

10:30AM-12:30PM: Abstract Number: 2243

Differences In GDF-15 Levels In Rheumatoid Arthritis Patients With Remission Or Mild Disease Activity Are Associated With Fewer Depressive Symptoms: Clinical Data And Bioinformatic Analysis

10:30AM-12:30PM: Abstract Number: 2246

Different Populations, Different SDAI Cut-Off? A Proposal for a New Remission Threshold in Brazilian RA Patients from a National Multicenter Study

10:30AM-12:30PM: Abstract Number: 2251

Dual Diagnoses, Diminished Survival: Association between rheumatoid arthritis and survival among older adults with lung cancer

10:30AM-12:30PM: Abstract Number: 2234

Early Sustained Remission Resulted in Superior Long-term Patient-Reported Outcomes in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2248

Elevated Anti-PAD Autoantibodies in a Singaporean Chinese Rheumatoid Arthritis (RA) Cohort with Rheumatoid Factor (RF) and Anti-Citrullinated Protein Antibodies (ACPA) Positivity: A Case-control Exploratory Study

10:30AM-12:30PM: Abstract Number: 2249

Evaluation of a Screening Tool for Identifying Risk of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with Targeted Therapies

10:30AM-12:30PM: Abstract Number: 2260

Generative AI model identifies patients with Rheumatoid Arthritis (RA) months prior the diagnosis date: results from a large real-world RA cohort

10:30AM-12:30PM: Abstract Number: 2257

Impact of Family History of RA in Patients Evaluated for Arthralgia: A Comprehensive Analysis of the Reuma-check Cohort

10:30AM-12:30PM: Abstract Number: 2238

Impact of Type 2 Diabetes on Cardiovascular and Renal Outcomes in Rheumatoid Arthritis: Insights from a Large-Scale Multi-Center Analysis

10:30AM-12:30PM: Abstract Number: 2256

Improved Outcomes of Acute Myocardial Infarction Among Patients with Rheumatoid Arthritis: A Propensity Matched National Study

10:30AM-12:30PM: Abstract Number: 2239

Increased Cardiovascular Morbidity in Patients with Rheumatoid Arthritis and Type 2 Diabetes: A Large-Scale Electronic Health Record Analysis

10:30AM-12:30PM: Abstract Number: 2231

Inverse Correlation Between Neutrophil Activation and Rheumatoid Factor Concentrations in Rheumatoid Arthritis (RA)

10:30AM-12:30PM: Abstract Number: 2259

Lung Transplant Outcomes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis and Meta-analysis

10:30AM-12:30PM: Abstract Number: 2264

Male Sex and Obesity Are Risk Factors for Sarcopenia in RA: Korea National Health and Nutrition Survey 2008–2011

10:30AM-12:30PM: Abstract Number: 2229

National Multicenter study of Baricitinib in Rheumatoid Arthritis – Interstitial Lung Disease: effectiveness and progressive lung disease

10:30AM-12:30PM: Abstract Number: 2261

Palindromic Rheumatism and Predictors of Progression to Rheumatoid Arthritis: Experience from a Tertiary Care Center in Northern India

10:30AM-12:30PM: Abstract Number: 2235

Proportion of Early Rheumatoid Arthritis Patients with Improved, Stable, or Worsened Lung Function Over 1-Year: Results from a Multicenter, Prospective Cohort Study

10:30AM-12:30PM: Abstract Number: 2230

Racial and Ethnic Disparities in Rheumatoid Arthritis-Associated Interstitial Lung Disease and Their Impact on Antifibrotic Therapy

10:30AM-12:30PM: Abstract Number: 2241

RADAR: A Deep Learning Pipeline for Automated Scoring of Joint Damage in Rheumatoid Arthritis Radiographs

10:30AM-12:30PM: Abstract Number: 2232

Risk factors for hospitalizations in a large, contemporary rheumatoid arthritis patient cohort

10:30AM-12:30PM: Abstract Number: 2237

Safety of DMARD therapy in veterans with rheumatoid arthritis following melanoma diagnosis: a survival analysis

10:30AM-12:30PM: Abstract Number: 2233

Spatial Multi-omics Demonstrates Shared Immune States Across Autoimmune Diseases and Target Tissues in the Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Diseases Network (AMP AIM)

10:30AM-12:30PM: Abstract Number: 2227

The Paraoxonase-1 Q192R Polymorphism is Associated with Increased Risk of Incident Clinical Rheumatoid Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population

10:30AM-12:30PM: Abstract Number: 2236

Treatment-induced autoantibodies in Rheumatoid Arthritis patients receiving anti-TNF inhibitors or JAK inhibitors

10:30AM-12:30PM: Abstract Number: 2253

Wrist-worn Wearable Device Data Can Be a New Digital Biomarker For Disease Activity In Rheumatoid Arthritis: a Multicenter Single-arm Prospective Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].